<p>Invivyd, Inc.（纳斯达克代码：IVVD - 获取免费报告）董事 Kevin Mclaughlin 于 11 月 19 日星期三购买了 50,000 股该股票。每股的平均成本为 2.50 美元，总交易额为 125,000.00 美元。收购完成后，该董事直接持有 50,000 股公司的股票，估值约为 125,000 美元。这笔交易代表了其持股的∞增长。此次购买在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
<h2>Invivyd 股票表现</h2>
<p>IVVD 股票在周四的交易中下跌 0.10 美元，跌至 2.40 美元。该公司的交易量为 4,802,679 股，而其平均交易量为 7,971,830 股。该公司的市值为 5.595 亿美元，市盈率为-5.11，贝塔值为 0.64。Invivyd, Inc.的年内最低价为 0.35 美元，年内最高价为 3.07 美元。该股票的 50 日移动平均价格为 1.64 美元，200 日移动平均价格为 1.09 美元。</p>
<p>Invivyd（纳斯达克代码：IVVD - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告本季度每股收益（EPS）为-0.06 美元，低于分析师一致预期的-0.05 美元，差距为 0.01 美元。该公司本季度的收入为 1313 万美元，而一致预期为 1200 万美元。Invivyd 的股本回报率为-92.97%，净利润率为-119.63%。研究分析师平均预计 Invivyd, Inc.在当前财政年度的每股收益将为-1.64 美元。</p>
<h2>对 Invivyd 的对冲基金看法</h2>
<p>一些机构投资者最近增加或减少了对该股票的持仓。Catalyst Funds Management Pty Ltd 在第二季度以约 27,000 美元的估值收购了 Invivyd 的新股份。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Invivyd 的股份增加了 238.6%。Vanguard Personalized Indexing Management LLC 现在拥有 39,941 股公司的股票，估值为 29,000 美元，此前在上个季度又收购了 28,146 股。美国银行（Bank of America Corp DE）在第三季度将其在 Invivyd 的股份增加了 330.5%。美国银行（Bank of America Corp DE）现在拥有 49,252 股公司的股票，估值为 54,000 美元，此前在上个季度又收购了 37,811 股。Nuveen LLC 在第一季度以 65,000 美元的估值收购了 Invivyd 的新股份。最后，XTX Topco Ltd 在第一季度以 66,000 美元的估值收购了 Invivyd 的新股份。目前，70.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>IVVD 最近成为几份分析师报告的主题。Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Invivyd 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 13 日星期四的报告中将 Invivyd 的评级从 “强烈卖出” 上调至 “持有”。HC Wainwright 在 10 月 31 日星期五的研究报告中将 Invivyd 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 “买入” 评级。Cantor Fitzgerald 在 10 月 6 日星期一的研究报告中开始覆盖 Invivyd 股票。他们设定了 “增持” 评级和 10.00 美元的目标价。最后，D. Boral Capital 在 10 月 6 日星期一的报告中将 Invivyd 的目标价从 1.00 美元上调至 2.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 7.33 美元。</p>
<p><strong>查看我们关于 IVVD 的最新研究报告</strong></p>
<h2>关于 Invivyd</h2>
<p>（获取免费报告）</p>
<p>Invivyd, Inc.是一家商业阶段的生物制药公司，专注于在美国发现、开发和商业化基于抗体的传染病解决方案。该公司开发了 INVYMAB，这是一个将病毒监测和预测建模与先进抗体工程相结合的平台。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Invivyd 更好</li>
<li>什么是股息之王？</li>
<li>Joby 和 Archer 在阿联酋开创新的战略篇章</li>
<li>支撑和阻力的基础知识</li>
<li>在底部崩溃前要卖出的三只投机股票</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>价格折扣零售之王？为什么 TJX 看起来准备突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Invivyd 吗？</h2>
<p>在你考虑 Invivyd 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前...而 Invivyd 并不在名单上。</p>
<p>虽然 Invivyd 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IVVD

<p>Invivyd, Inc. 的董事 Kevin Mclaughlin 以每股 2.50 美元的价格购买了 50,000 股，总计 125,000 美元。这笔交易在 SEC 文件中披露，标志着他持股的显著增加。Invivyd 的股票表现略有下降，目前交易价格为 2.40 美元。分析师的评级不一，普遍目标价为 7.33 美元。该公司专注于针对传染病的抗体解决方案</p>

<p>Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Kevin Mclaughlin bought 50,000 shares of the stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director directly owned 50,000 shares of the company's stock, valued at approximately $125,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>Invivyd, Inc.（纳斯达克代码：IVVD - 获取免费报告）董事 Kevin Mclaughlin 于 11 月 19 日星期三购买了 50,000 股该股票。每股的平均成本为 2.50 美元，总交易额为 125,000.00 美元。收购完成后，该董事直接持有 50,000 股公司的股票，估值约为 125,000 美元。这笔交易代表了其持股的∞增长。此次购买在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
</div><h2>Invivyd Stock Performance</h2>
<div class="lb-trans"><h2>Invivyd 股票表现</h2>
</div><p>Shares of IVVD stock traded down $0.10 during trading on Thursday, hitting $2.40. The company had a trading volume of 4,802,679 shares, compared to its average volume of 7,971,830. The firm has a market capitalization of $559.50 million, a P/E ratio of -5.11 and a beta of 0.64. Invivyd, Inc. has a one year low of $0.35 and a one year high of $3.07. The stock's 50-day moving average price is $1.64 and its 200 day moving average price is $1.09.</p>
<div class="lb-trans"><p>IVVD 股票在周四的交易中下跌 0.10 美元，跌至 2.40 美元。该公司的交易量为 4,802,679 股，而其平均交易量为 7,971,830 股。该公司的市值为 5.595 亿美元，市盈率为-5.11，贝塔值为 0.64。Invivyd, Inc.的年内最低价为 0.35 美元，年内最高价为 3.07 美元。该股票的 50 日移动平均价格为 1.64 美元，200 日移动平均价格为 1.09 美元。</p>
</div><p>Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, research analysts anticipate that Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Invivyd（纳斯达克代码：IVVD - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告本季度每股收益（EPS）为-0.06 美元，低于分析师一致预期的-0.05 美元，差距为 0.01 美元。该公司本季度的收入为 1313 万美元，而一致预期为 1200 万美元。Invivyd 的股本回报率为-92.97%，净利润率为-119.63%。研究分析师平均预计 Invivyd, Inc.在当前财政年度的每股收益将为-1.64 美元。</p>
</div><h2>Hedge Funds Weigh In On Invivyd</h2>
<div class="lb-trans"><h2>对 Invivyd 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd acquired a new stake in Invivyd in the second quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after acquiring an additional 28,146 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Invivyd by 330.5% in the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company's stock valued at $54,000 after acquiring an additional 37,811 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Invivyd during the 1st quarter valued at $65,000. Finally, XTX Topco Ltd bought a new stake in Invivyd during the 1st quarter worth $66,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该股票的持仓。Catalyst Funds Management Pty Ltd 在第二季度以约 27,000 美元的估值收购了 Invivyd 的新股份。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Invivyd 的股份增加了 238.6%。Vanguard Personalized Indexing Management LLC 现在拥有 39,941 股公司的股票，估值为 29,000 美元，此前在上个季度又收购了 28,146 股。美国银行（Bank of America Corp DE）在第三季度将其在 Invivyd 的股份增加了 330.5%。美国银行（Bank of America Corp DE）现在拥有 49,252 股公司的股票，估值为 54,000 美元，此前在上个季度又收购了 37,811 股。Nuveen LLC 在第一季度以 65,000 美元的估值收购了 Invivyd 的新股份。最后，XTX Topco Ltd 在第一季度以 66,000 美元的估值收购了 Invivyd 的新股份。目前，70.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>IVVD has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Invivyd in a research report on Friday, October 31st. Zacks Research raised shares of Invivyd from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, November 13th. HC Wainwright lifted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Cantor Fitzgerald began coverage on shares of Invivyd in a research report on Monday, October 6th. They set an &#34;overweight&#34; rating and a $10.00 price objective for the company. Finally, D. Boral Capital raised their target price on Invivyd from $1.00 to $2.00 and gave the company a &#34;buy&#34; rating in a report on Monday, October 6th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus price target of $7.33.</p>
<div class="lb-trans"><p>IVVD 最近成为几份分析师报告的主题。Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Invivyd 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 13 日星期四的报告中将 Invivyd 的评级从 “强烈卖出” 上调至 “持有”。HC Wainwright 在 10 月 31 日星期五的研究报告中将 Invivyd 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 “买入” 评级。Cantor Fitzgerald 在 10 月 6 日星期一的研究报告中开始覆盖 Invivyd 股票。他们设定了 “增持” 评级和 10.00 美元的目标价。最后，D. Boral Capital 在 10 月 6 日星期一的报告中将 Invivyd 的目标价从 1.00 美元上调至 2.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 7.33 美元。</p>
</div><p><strong>View Our Latest Research Report on IVVD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IVVD 的最新研究报告</strong></p>
</div><h2>About Invivyd</h2>
<div class="lb-trans"><h2>关于 Invivyd</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.</p>
<div class="lb-trans"><p>Invivyd, Inc.是一家商业阶段的生物制药公司，专注于在美国发现、开发和商业化基于抗体的传染病解决方案。该公司开发了 INVYMAB，这是一个将病毒监测和预测建模与先进抗体工程相结合的平台。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Invivyd</li>
<li>What is a Dividend King?</li>
<li>Joby and Archer Forge a New Strategic Chapter in the UAE</li>
<li>The Basics of Support and Resistance</li>
<li>3 Speculative Stocks to Sell Before the Bottom Drops Out</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>The Off-Price Retail King? Why TJX Looks Ready to Break Out</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Invivyd 更好</li>
<li>什么是股息之王？</li>
<li>Joby 和 Archer 在阿联酋开创新的战略篇章</li>
<li>支撑和阻力的基础知识</li>
<li>在底部崩溃前要卖出的三只投机股票</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>价格折扣零售之王？为什么 TJX 看起来准备突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IVVD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Invivyd Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Invivyd 吗？</h2>
</div><p>Before you consider Invivyd, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Invivyd 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前...而 Invivyd 并不在名单上。</p>
</div><p>While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Invivyd 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Invivyd（NASDAQ:IVVD）董事 Kevin Mclaughlin 收购了 50,000 股股票